Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2020 from OUS - Department of Cancer Genetics
50 publications found
Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
Clin Transl Radiat Oncol, 22, 15-21
DOI 10.1016/j.ctro.2020.02.005, PubMed 32181373
Improved detection of differentially represented DNA barcodes for high-throughput clonal phenomics
Mol Syst Biol, 16 (3), e9195
DOI 10.15252/msb.20199195, PubMed 32187448
Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer
Cancer Rep (Hoboken), 3 (3), e1248
DOI 10.1002/cnr2.1248, PubMed 32671987
Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions
NPJ Breast Cancer, 6, 26
DOI 10.1038/s41523-020-0167-x, PubMed 32577501
Epigenome-wide gene-age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients
Aging (Albany NY), 12 (11), 10642-10662
DOI 10.18632/aging.103284, PubMed 32511103
MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers
BMC Cancer, 20 (1), 377
DOI 10.1186/s12885-020-06857-7, PubMed 32370743
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Lung Cancer, 143, 27-35
DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138
AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer
iScience, 23 (11), 101649
DOI 10.1016/j.isci.2020.101649, PubMed 33103086
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis
Nat Commun, 11 (1), 312
DOI 10.1038/s41467-019-14100-6, PubMed 31949161
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nat Genet, 52 (1), 56-73
DOI 10.1038/s41588-019-0537-1, PubMed 31911677
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia
Ann Intern Med, 173 (12), 989-1001
DOI 10.7326/M20-1443, PubMed 32894695
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
Genet Epidemiol, 44 (5), 442-468
DOI 10.1002/gepi.22288, PubMed 32115800
JASPAR 2020: update of the open-access database of transcription factor binding profiles
Nucleic Acids Res, 48 (D1), D87-D92
DOI 10.1093/nar/gkz1001, PubMed 31701148
Re-definition of claudin-low as a breast cancer phenotype
Nat Commun, 11 (1), 1787
DOI 10.1038/s41467-020-15574-5, PubMed 32286297
Antibody combinations for optimized staining of macrophages in human lung tumours
Scand J Immunol, 92 (1), e12889
DOI 10.1111/sji.12889, PubMed 32299134
MirGeneDB 2.0: the metazoan microRNA complement
Nucleic Acids Res, 48 (D1), D132-D141
DOI 10.1093/nar/gkz885, PubMed 31598695
Distribution of allele frequencies for genes associated with physical activity and/or physical capacity in a homogenous Norwegian cohort- a cross-sectional study
BMC Genet, 21 (1), 8
DOI 10.1186/s12863-020-0813-1, PubMed 31973699
Modeling molecular development of breast cancer in canine mammary tumors
Genome Res (in press)
DOI 10.1101/gr.256388.119, PubMed 33361113
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
Int J Cancer, 147 (10), 2957-2966
DOI 10.1002/ijc.33121, PubMed 32468587
Aplastic anaemia
Tidsskr. Nor. Laegeforen., 140 (18), 1897-1900
Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
Front Oncol, 10, 590755
DOI 10.3389/fonc.2020.590755, PubMed 33324562
Characterizing the Quality of Insight by Interactions: A Case Study
IEEE Trans Vis Comput Graph (in press)
DOI 10.1109/TVCG.2020.2977634, PubMed 32142444
Radiological review of prior screening mammograms of screen-detected breast cancer
Eur Radiol
DOI 10.1007/s00330-020-07130-y, PubMed 33001307
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Nucleic Acids Res, 48 (W1), W488-W493
DOI 10.1093/nar/gkaa216, PubMed 32246720
SynergyFinder: a web application for analyzing drug combination dose-response matrix data
Bioinformatics, 36 (8), 2645
DOI 10.1093/bioinformatics/btaa102, PubMed 32118251
Pan-cancer analysis of whole genomes
Nature, 578 (7793), 82-93
DOI 10.1038/s41586-020-1969-6, PubMed 32025007
Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients
Mol Oncol, 14 (11), 2759-2774
DOI 10.1002/1878-0261.12785, PubMed 33448640
Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects
Nat Commun, 11 (1), 6136
DOI 10.1038/s41467-020-19950-z, PubMed 33262326
The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers
Sci Rep, 10 (1), 1277
DOI 10.1038/s41598-020-57759-4, PubMed 31992741
Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk
Am J Hum Genet, 107 (5), 837-848
DOI 10.1016/j.ajhg.2020.09.001, PubMed 33022221
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163
Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows
Clin Chem, 66 (1), 149-160
DOI 10.1373/clinchem.2019.306837, PubMed 31628139
Spatial transcriptomics inferred from pathology whole-slide images links tumor heterogeneity to survival in breast and lung cancer
Sci Rep, 10 (1), 18802
DOI 10.1038/s41598-020-75708-z, PubMed 33139755
Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
Acta Oncol, 60 (2), 149-156
DOI 10.1080/0284186X.2020.1854851, PubMed 33356733
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Commun Biol, 3 (1), 153
DOI 10.1038/s42003-020-0884-6, PubMed 32242091
Multiobjective optimization identifies cancer-selective combination therapies
PLoS Comput Biol, 16 (12), e1008538
DOI 10.1371/journal.pcbi.1008538, PubMed 33370253
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
Future perspectives of surgical treatment of breast cancer
Ann Med Surg (Lond), 59, 93-95
DOI 10.1016/j.amsu.2020.09.021, PubMed 33005399
Modern surgical treatment of breast cancer
Ann Med Surg (Lond), 56, 95-107
DOI 10.1016/j.amsu.2020.06.016, PubMed 32637082
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
Scand J Immunol, 92 (2), e12893
DOI 10.1111/sji.12893, PubMed 32433774
Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
Breast Cancer Res, 22 (1), 73
DOI 10.1186/s13058-020-01295-6, PubMed 32605588
Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
Oncoimmunology, 9 (1), 1824644
DOI 10.1080/2162402X.2020.1824644, PubMed 33457104
A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis
Mol Oncol, 14 (2), 235-247
DOI 10.1002/1878-0261.12620, PubMed 31851411
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909
Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer
Comput Struct Biotechnol J, 18, 3819-3832
DOI 10.1016/j.csbj.2020.11.001, PubMed 33335681
Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling
Cancers (Basel), 12 (6)
DOI 10.3390/cancers12061588, PubMed 32560092
Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer
Clin Lung Cancer (in press)
DOI 10.1016/j.cllc.2020.09.018, PubMed 33214079
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
Nat Genet, 52 (6), 572-581
DOI 10.1038/s41588-020-0609-2, PubMed 32424353
Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects
Chest, 158 (2), 808-819
DOI 10.1016/j.chest.2020.01.048, PubMed 32113923
Subtype-specific transcriptional regulators in breast tumors subjected to genetic and epigenetic alterations
Bioinformatics, 36 (4), 994-999
DOI 10.1093/bioinformatics/btz709, PubMed 31529022